Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering

Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh

Rocket Pharmaceuticals, Inc. (NASDAQ:... More

Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)

Pre-Open Movers

Synthorx, Inc. (NASDAQ: THOR) 169.3% HIGHER; Sanofi (NYSE: SNY) and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

XBiotech Inc. (NASDAQ:... More

Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets

Chardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while maintaining a Buy rating.

The analyst commented, "On 8 November, Rocket Pharmaceuticals presented preliminary data on ex vivo lentiviral gene therapy RP-L102 for Fanconi anemia (FA), manufactured with commercial-grade "Process B", demonstrating (1) 2-3x higher product vector copy numbers (VCNs) vs. Process A product, and (2) signals of engraftment in patients at 6 months. The data, presented in a poster at the American Society of Hematology (ASH) 2019 Annual... More

Rocket Pharmaceuticals (RCKT) PT Raised to $42 at Oppenheimer Following Pipeline Update

Oppenheimer analyst Esther Rajavelu raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $42.00 (from $36.00) while maintaining a Outperform rating.

The analyst commented, "RCKT management presented a pipeline update that included 1) preliminary RP-L102 Process-B data demonstrating early engraftment signals and clinical stability in two... More

Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces preliminary data from its Phase 1/2 clinical trial of RP-L201, the Companys lentiviral vector... More

Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces encouraging preliminary results from its Phase 1 trial of commercial-grade RP-L102 Process B for Fanconi Anemia (FA) at the 61st American Society of Hematology (ASH) Annual Meeting. The data are highlighted in a poster presentation by Agnieszka Czechowicz M.D., Ph.D., Assistant Professor of Pediatrics,... More

Rocket Pharmaceuticals (RCKT) PT Raised to $41 at Baird, Added to Fresh Pick List

Baird analyst Madhu Kumar raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $41.00 (from $30.00) while maintaining a Outperform rating.

The analyst comments "Prior to Rocket Pharmaceuticals' (RCKT) data release at the American Society... More